AI Article Synopsis
- Fingolimod is an oral drug for treating multiple sclerosis that works by keeping specific immune cells (lymphocytes) trapped in lymph nodes, limiting their circulation in the blood and movement into the central nervous system (CNS).
- Initial Phase III trials showed similar infection rates compared to control groups, but later surveillance found links to opportunistic infections like cryptococcosis.
- The report discusses a case of cryptococcal meningoencephalitis related to fingolimod use, highlights the occurrence of immune reconstitution inflammatory syndrome (IRIS) after stopping the medication, and proposes a strategy for better monitoring and risk management.
Article Abstract
Fingolimod is an oral medication for multiple sclerosis that sequesters certain subsets of lymphocytes in lymph nodes, reducing egress into blood and their subsequent CNS migration. The initial multi-site randomized Phase III controlled trials found rates of infection similar to those in control groups. However, post-marketing surveillance has revealed an association with several opportunistic infections, including cryptococcosis. We report a case of fingolimod-related cryptococcal meningoencephalitis and IRIS after drug discontinuation and suggest a surveillance and risk mitigation strategy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2021.103072 | DOI Listing |
Publication Analysis
Top Keywords
fingolimod-related cryptococcal
8
cryptococcal meningoencephalitis
8
multiple sclerosis
8
meningoencephalitis immune
4
immune reconstitution
4
reconstitution inflammatory
4
inflammatory syndrome
4
syndrome patient
4
patient multiple
4
sclerosis fingolimod
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!